Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc.

Biotech R&D: A Decade of Strategic Investments

__timestampIntra-Cellular Therapies, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 201421226345293000
Thursday, January 1, 2015877180741002000
Friday, January 1, 201693831530888000
Sunday, January 1, 20177941900919623000
Monday, January 1, 201813216691330421000
Tuesday, January 1, 20198912483834794000
Wednesday, January 1, 20206578213728304000
Friday, January 1, 20218884551356886000
Saturday, January 1, 2022134715000100894000
Sunday, January 1, 2023180142000159765000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.

Intra-Cellular Therapies, Inc.

From 2014 to 2023, Intra-Cellular Therapies, Inc. has consistently increased its R&D spending, peaking in 2023 with a 750% increase from its 2014 levels. This upward trend underscores the company's dedication to advancing its therapeutic pipeline.

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., on the other hand, has shown a more volatile pattern. Starting with minimal R&D expenses in 2014, the company saw a dramatic rise by 2023, marking a staggering 54,000% increase. This surge reflects Viridian's strategic pivot towards aggressive research initiatives.

Both companies exemplify the dynamic nature of the biotech industry, where strategic R&D investments can lead to groundbreaking innovations.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025